Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Royalty Pharma plc - Class A Ordinary Shares
(NQ:
RPRX
)
34.02
+0.90 (+2.72%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 16, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Royalty Pharma plc - Class A Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
Next >
If You Own These 3 Growth Stocks, You Might Want to Rethink Your Position
October 18, 2022
There may be more trouble on the horizon for these stocks than most investors are seeing right now.
Via
The Motley Fool
Royalty Pharma Declares Fourth Quarter 2022 Dividend
October 17, 2022
From
Royalty Pharma plc
Via
GlobeNewswire
Jim Cramer Likes This Biotechnology Stock: 'It's Not Big, But It's Not Bad'
October 14, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Royalty Pharma plc (NASDAQ: RPRX) and will stick with it. "It’s not big, but it’s not bad," he added.
Via
Benzinga
Royalty Pharma Announces Expansion of Leadership Team
October 12, 2022
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces R&D Funding Collaboration With Merck
October 12, 2022
Novel collaboration structure supports pipeline innovation
From
Royalty Pharma plc
Via
GlobeNewswire
Expert Ratings for Royalty Pharma
August 08, 2022
Within the last quarter, Royalty Pharma (NASDAQ:RPRX) has observed the following analyst ratings:
Via
Benzinga
Royalty Pharma: Q2 Earnings Insights
August 04, 2022
Royalty Pharma (NASDAQ:RPRX) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings
September 19, 2022
Via
Benzinga
Royalty Pharma's Return On Capital Employed Insights
August 22, 2022
Pulled from Benzinga Pro data, Royalty Pharma (NASDAQ:RPRX) posted Q2 earnings of $491.60 million, an increase from Q1 of 283.81%. Sales dropped to $535.96 million, a 4.63% decrease between quarters.
Via
Benzinga
Warren Buffett's Berkshire Takes Another Bite Of Apple, Boosts Energy Holdings, Cashes Out Of Verizon: What 13F Filing Reveals
August 16, 2022
Warren Buffett-owned Berkshire Hathaway, Inc.’s (NYSE: BRK-A) (NYSE: BRK-B) portfolio saw some noteworthy and a few other nominal changes in the second quarter, according to the company's 13F filing.
Via
Benzinga
Jim Cramer Shares His Takes On First Solar, Royalty Pharma And More
August 11, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Royalty Pharma PLC (NASDAQ: RPRX) is going higher. "Hold on to it."
Via
Benzinga
The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures
July 14, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Expert Ratings for Royalty Pharma
June 14, 2022
Royalty Pharma (NASDAQ:RPRX) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Theravance Biopharma, Innoviva Gain On Selling TRELEGY ELLIPTA Royalty Interests
July 13, 2022
Via
Benzinga
Warren Buffett Stocks: Royalty Pharma plc
July 08, 2022
As of March 31st, 2022, Buffett’s Berkshire Hathaway owned about 1.5 million shares of Royalty Pharma plc for a market value of $58.3 million. Let's analyze the healthcare company in greater detail.
Via
Talk Markets
This Analyst Thinks Blueprint Medicines' Non-Dilutive Funding 'Deflates M&A Speculation'
June 30, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022
June 14, 2022
Upgrades
Via
Benzinga
Executives Sell Around $325M Of 3 Stocks
May 24, 2022
Gold futures traded higher this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
Expert Ratings for Royalty Pharma
May 13, 2022
Analysts have provided the following ratings for Royalty Pharma (NASDAQ:RPRX) within the last quarter:
Via
Benzinga
Royalty Pharma: Q1 Earnings Insights
May 05, 2022
Royalty Pharma (NASDAQ:RPRX) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Management of Technology Companies Continue Selling - Zillow (Z)
May 31, 2022
In a week where we saw most market indices rebound sharply, insiders scaled back their buying after three weeks of elevated buying. Buying declined by 64% in absolute dollar terms and 26% in terms of...
Via
Benzinga
Royalty Pharma Earnings Perspective: Return On Capital Employed
May 27, 2022
Pulled from Benzinga Pro data, Royalty Pharma (NASDAQ:RPRX) posted Q1 earnings of $128.08 million, an increase from Q4 of 138.64%. Sales dropped to $562.00 million, a 2.43% decrease between quarters.
Via
Benzinga
Warren Buffett Stocks: Berkshire Hathaway Goes On Offense In Stock Market, Adds More Apple
May 16, 2022
Buffett's Berkshire added to Apple and Chevron during the Q1 sell-off. More details to come.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For May 13, 2022
May 13, 2022
Upgrades
Via
Benzinga
Recap: Royalty Pharma Q1 Earnings
May 05, 2022
Royalty Pharma (NASDAQ:RPRX) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
How To Attend Royalty Pharma Q1 2022 Earnings Conference Call
May 03, 2022
Royalty Pharma (NASDAQ:RPRX) will host a conference call at 08:00 AM ET on May 5, 2022, to discuss Q1 2022 earnings results. How to Attend Royalty Pharma (RPRX) Conference Call Follow this link to...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022
April 14, 2022
Upgrades
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
April 06, 2022
Upgrades
Via
Benzinga
Expedia And 3 Other Stocks Insiders Are Selling
March 31, 2022
Although gold futures traded lower on Thursday, there were a few notable insider trades. When insiders sell shares, it indicates their concern in the company’s prospects or...
Via
Benzinga
Hopeful Golden Cross Forms On Royalty Pharma's Chart
March 01, 2022
If history is any guide, there may be good fortune ahead for shares of Royalty Pharma (NASDAQ:RPRX). A so-called "golden cross" has formed on its chart and, not surprisingly,...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.